Study details
Enrolling now
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
EpicentRx, Inc.
NCT IDNCT04673942ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
140
Study length
about 5.9 years
Ages
18+
Locations
6 sites in CA, OH, TX
About this study
Researchers are testing the safety and tolerability of AdAPT-001, an oncolytic virus. The trial also aims to determine if AdAPT-001 is effective when used alone or with a checkpoint inhibitor.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive AdAPT-001
- 2.Take Checkpoint Inhibitor, Immune
PhasePhase 2
Primary goalDose Limiting Toxicities (DLT)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Dose Limiting Toxicities (DLT), Maximum tolerated dose
Secondary: Objective response rate
Body systems
Oncology